Mads Hald Andersen Selected Research

HLA-A2 Antigen (HLA A2 Antigen)

1/2021	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner.
1/2017	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.
1/2014	Spontaneous presence of FOXO3-specific T cells in cancer patients.
5/2009	The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
3/2009	CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
1/2005	Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.
3/2004	HLA-B35-restricted immune responses against survivin in cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mads Hald Andersen Research Topics

Disease

101	Neoplasms (Cancer) 01/2022 - 04/2002
39	Melanoma (Melanoma, Malignant) 04/2022 - 04/2002
6	Breast Neoplasms (Breast Cancer) 02/2011 - 02/2004
5	Hematologic Neoplasms (Hematological Malignancy) 02/2020 - 03/2005
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2014
3	Disease Progression 01/2022 - 03/2006
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 05/2020 - 04/2016
3	Multiple Myeloma 01/2020 - 01/2016
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 09/2006
2	Philadelphia Chromosome 01/2021 - 07/2020
2	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 10/2019
2	Lymphoma (Lymphomas) 03/2019 - 10/2007
2	Inflammation (Inflammations) 01/2018 - 01/2017
2	Testicular Neoplasms (Testicular Cancer) 01/2018 - 03/2005
2	Squamous Cell Carcinoma of Head and Neck 01/2012 - 08/2011
2	Renal Cell Carcinoma (Grawitz Tumor) 02/2011 - 12/2003
2	Colonic Neoplasms (Colon Cancer) 12/2008 - 10/2007
2	Leukemia 10/2007 - 03/2005
2	Neoplasm Metastasis (Metastasis) 01/2005 - 05/2004
1	Reinfection 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 02/2021
1	Turcot syndrome 01/2021
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Microsatellite Instability 01/2021
1	Injection Site Reaction 01/2020
1	Hypersensitivity (Allergy) 01/2020
1	Carcinoma (Carcinomatosis) 01/2020
1	Polycythemia Vera 10/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	Hodgkin Disease (Hodgkin's Disease) 01/2019
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Bacterial Infections (Bacterial Infection) 04/2018
1	Bacteremia 04/2018
1	Soft Tissue Infections 04/2018
1	Sepsis (Septicemia) 04/2018
1	Choriocarcinoma 01/2018
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018

Drug/Important Bio-Agent (IBA)

39	Peptides (Polypeptides)IBA 01/2022 - 04/2002
34	AntigensIBA 01/2022 - 06/2002
29	EpitopesIBA 01/2022 - 06/2002
23	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2004
22	VaccinesIBA 04/2022 - 05/2004
17	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 12/2003
12	EnzymesIBA 01/2022 - 03/2009
12	SurvivinIBA 01/2017 - 02/2004
10	CytokinesIBA 01/2021 - 06/2002
9	Protein Subunit VaccinesIBA 01/2022 - 01/2014
9	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 12/2021 - 09/2009
8	LigandsIBA 12/2021 - 02/2011
8	Interleukin-2 (IL2)IBA 01/2016 - 06/2002
7	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2021 - 03/2004
5	Arginine (L-Arginine)FDA Link 11/2021 - 01/2018
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2015
3	CalreticulinIBA 01/2021 - 01/2019
3	Monatide (IMS 3015)IBA 01/2021 - 01/2017
3	Chimeric Antigen ReceptorsIBA 01/2020 - 01/2019
3	Monoclonal AntibodiesIBA 01/2020 - 11/2008
3	Cancer VaccinesIBA 10/2019 - 05/2009
3	Pharmaceutical PreparationsIBA 01/2019 - 01/2010
3	Histocompatibility Antigens Class IIBA 01/2017 - 06/2002
3	Heme (Haem)IBA 01/2015 - 08/2009
3	InterleukinsIBA 01/2015 - 08/2011
3	HLA Antigens (Human Leukocyte Antigens)IBA 03/2013 - 04/2008
3	Cyclin B1IBA 01/2012 - 03/2009
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2009 - 04/2002
2	NivolumabIBA 04/2022 - 12/2021
2	Blocking AntibodiesIBA 02/2021 - 01/2019
2	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 12/2012
2	B7-H1 AntigenIBA 01/2019 - 01/2018
2	Temozolomide (Temodar)FDA LinkGeneric 01/2017 - 02/2013
2	IpilimumabIBA 01/2016 - 01/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 10/2012
2	AntibodiesIBA 01/2015 - 02/2011
2	InterferonsIBA 01/2015 - 02/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 03/2006
2	Biological ProductsIBA 03/2011 - 12/2003
2	CyclinsIBA 02/2011 - 03/2009
2	Inhibitor of Apoptosis ProteinsIBA 08/2009 - 02/2004
2	HLA-A Antigens (HLA-A)IBA 03/2006 - 03/2005
1	Galectin 3 (LGALS3)IBA 01/2022
1	PyrrolesIBA 01/2022
1	ArginaseIBA 11/2021
1	MicroRNAs (MicroRNA)IBA 05/2020
1	Immunomodulating AgentsIBA 10/2019
1	ruxolitinibIBA 10/2019
1	c-Mer Tyrosine KinaseIBA 09/2019
1	Bispecific AntibodiesIBA 01/2019
1	Rituximab (Mabthera)FDA Link 01/2019
1	staphylococcal alpha-toxinIBA 01/2019
1	Enterotoxins (Enterotoxin)IBA 04/2018
1	Azacitidine (5 Azacytidine)FDA Link 01/2018
1	Peptide LibraryIBA 01/2018

Therapy/Procedure

31	Immunotherapy 11/2021 - 06/2002
27	Therapeutics 12/2021 - 12/2003
7	Drug Therapy (Chemotherapy) 01/2020 - 03/2005
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2020 - 08/2012
1	Aftercare (After-Treatment) 12/2021
1	Radiotherapy 10/2019